GC Genome Presents AI-Based Liquid Biopsy at the 2022 American Association for Cancer Research (AACR) Annual Meeting | Business

YONGIN, South Korea–(BUSINESS WIRE)–April 15, 2022–

GC Genome, a leading company in genomic diagnostics, is pleased to announce that the company has presented the deep learning algorithm that detects and classifies multiple cancers using cf-WGS (whole genome sequencing cell-free DNA), summarized in a poster session held at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.

Data from the presentation shows that it detects abnormal patterns of cancer more sensitively and accurately than the original liquid biopsy because it applies a deep learning algorithm on whole genome sequencing data, which discovers variants structural with a distinct tumor type.

In addition, this biopsy can detect the existence of 9 major cancers (△ lung cancer △ colorectal cancer △ breast cancer △ liver cancer △ pancreatic cancer △ cholangiocarcinoma △ head and neck cancer △ breast cancer ovary △ esophageal cancer) using whole genome sequencing (WGS) of circulating tumor DNA (ctDNA) in blood. Additionally, its “multicancer prediction” model can predict tumor-derived tissues related to 6 specific types of cancers. (△ lung cancer △ breast cancer △ liver cancer △ pancreatic cancer △ ovarian cancer △ esophageal cancer)

“We are excited to introduce AI-based liquid biopsy with GC Genome’s original technology applied,” said Eun-Hae Cho, Chief Technology Officer at GC Genome Research Center, “The data that will be presented at the This year’s AACR meeting demonstrate a major step forward in our commitment to providing clinicians and patients with a highly sensitive multi-cancer screening test where we believe cancer screening can save lives.

About GC Genome

GC Genome specializes in clinical genomics, which was established in August 2013 as a new member of the GC family, headquartered in Yong-in, South Korea. GC Genome is moving towards the goal of using genomic information for disease diagnosis, disease screening and also precision medicine. GC Genome leverages the latest technologies, including Next Generation Sequencing (NGS), to provide distinguished services with short turnaround times and affordable prices. In addition, GC Genome continues to invest heavily in R&D activities to develop services that meet people’s unmet needs and to participate in the advancement of various global and national research projects.

This press release may contain forward-looking statements, which express the current beliefs and expectations of the management of GC Genome. These statements do not represent any guarantees on the part of GC Genome or its management as to future performance and involve known and unknown risks, uncertainties and other factors. GC Genome undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statement it may make, except as required by law or stock exchange rules.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220414005921/en/

CONTACT: Investor/Media Contact

Sohee Kim

[email protected] Jun

[email protected] Kim

[email protected] Haeun Yoon

[email protected]




Copyright BusinessWire 2022.

PUBLISHED: 04/15/2022 03:28 / DISK: 04/15/2022 03:28


Copyright BusinessWire 2022.

Previous Commission acts for global food security and to support EU farmers and consumers - World
Next Heights Hosts Eight Local Mayors for Cen-Tex Sustainable Communities Event | Local News